Cover Image


View/Hide Left Panel

FDA. 2003b. FDA News. FDA Proposes Labeling and Manufacturing Standards for All Dietary Supplements. Online. Available at Accessed July 2, 2003.

FDA. 2003c. Safety reporting requirements for human drug and biological products. Proposed rule. Fed Regis 68:12406–12497.

Finney DJ. 1971. Statistical aspects of monitoring for dangers in drug therapy. Methods Inf Med 10:1–8.

Fletcher AP. 1991. Spontaneous adverse drug reaction reporting vs event monitoring: A comparison. J R Soc Med 84:341–344.

GAO (General Accounting Office). 1992. Cross Design Synthesis: A New Strategy for Medical Effectiveness Research. GAO/PEMD-92-18. Washington, DC: GAO.

Gardner MJ, Machin D, Campbell MJ. 1986. Use of check lists in assessing the statistical content of medical studies. Br Med J 292:810–812.

Goldman SA. 1996. The Clinical Impact of Adverse Event Reporting. A MedWatch Continuing Education Article. Food and Drug Administration. Available at Accessed February 25, 2003.

Goldman SA. 1998. Limitations and strengths of spontaneous reports data. Clin Ther 20:C40–C44.

Goldman SA, Kennedy DL, Lieberman R, eds. 1995. Clinical Therapeutics and the Recognition of Drug-Induced Disease. A MedWatch Continuing Education Article. Food and Drug Administration. Available at Accessed June 4, 2003.

Griggs B. 1997. Green Pharmacy. The History and Evolution of Western Herbal Medicine. 2nd ed. Rochester, VT: Healing Arts Press.

Hennekens CH, Buring JE, Mayrent SL. 1987. Epidemiology in Medicine. Boston: Little, Brown.

Hill AB. 1971. Principles of Medical Statistics. 9th ed. New York: Oxford University Press.

ICH (International Conference on Harmonisation). 1995. Guidance for Industry. E3. Structure and Content of Clinical Study Reports. Rockville, MD: Drug Information Branch, Center for Drug Evaluation and Research, FDA.

Ioannidis JP, Lau J. 2001. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. J Am Med Assoc 285:437–443.

Ioannidis JPA, Chew P, Lau J. 2002. Standardized retrieval of side effects data for metaanalysis of safety outcomes: A feasibility study in acute sinusitis. J Clin Epidemiol 55:619–626.

Karch FE, Smith CL, Kerzner B, Mazzullo JM, Weintraub M, Lasagna L. 1976. Adverse drug reactions—A matter of opinion. Clin Pharmacol Ther 19:489–492.

Kessler DA. 1993. Introducing MEDWatch: A new approach to reporting medication and device adverse effects and product problems. J Clin Res Drug Dev 7:183–190.

Koch-Weser J, Sellers EM, Zacest R. 1977. The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 11:75–78.

Lewis JA. 1981. Post-marketing surveillance: How many patients? Trends Pharmacol Sci 2:93–94.

Moher D, Schulz KF, Altman DG. 2001. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 1:2–8.

OIG (Office of Inspector General). 2001. Adverse Event Reporting for Dietary Supplements. An Inadequate Safety Valve. Online. Food and Drug Administration. Available at Accessed February 26, 2003.

Prance GT, Chadwick DJ, Marsh J, eds. 1994. Ethnobotany and the Search for New Drugs. Ciba Foundation Symposium 185. New York: John Wiley and Sons.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement